IDO1 and graft versus host disease: Despite the potent immunosuppressive activity observed in IFN-γ-primed MSCs, largely due to the IDO pathway, no clinical trials to date have employed IFN-γ-primed MSCs for the treatment and prophylaxis of GVHD.